昊天发展集团(00474.HK)与伊藤忠就Promethera Biosciences产品订立合作协议
格隆汇 9 月 15日丨昊天发展集团(00474.HK)发布公告,2020年9月15日,Aceso-Promethera Asia Company Limited、Promethera Biosciences S.A./N.V及伊藤忠商事株式会社订立更替及经修订合作协议,内容有关在亚洲授权、销售及分销若干专有的知识产权的治疗用途,当中涉及治疗人类尿素循环失调(UCD)、慢加急性肝衰竭(ACLF)及非酒精性脂肪肝炎(NASH)的扩增肝脏干细胞疗法及肝脏间质干细胞疗法。
根据披露,集团与Promethera Biosciences成立的合营公司Aceso-Promethera Asia拥有研究、开发、利用及商业化Promethera Biosciences在大中华及东南亚知识产权的独家权利,为免生疑问,当中不包括与制造有关的任何知识产权;Promethera Biosciences为建基于比利时的再生医学技术公司,负责开发及商业化用于治疗人类急性及慢性肝病患者的干细胞疗法;伊藤忠为一家以东京为本部的领先贸易公司,有意投资于亚洲新兴的再生医学市场。
Aceso-Promethera Asia及伊藤忠将为在亚洲指定地区于协定范围内治疗UCD、ACLF、NASH及其他适应症的产品业务机会研讨。预期订约方将参与信息共享,并主动就于指定地区授权、分销及销售产品的商机进行磋商。作为合作其中一环,Promethera Biosciences将负责产品生产。订约方订立合作协议旨在发展互惠互利的商业关系及利用各方的竞争优势于亚洲开发及商业化产品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.